Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Evaluating non-invasive methods for diagnosing portal hypertension

Official title: Noninvasive Tools for the Diagnosis of Porto-sinusoidal Vascular Disease: a Single-center, Prospective, Cohort Study

Run by Nanfang Hospital, Southern Medical University · NCT06500403 · Data updated 2026-11-12

This study is testing if measuring the stiffness of the liver and spleen can help diagnose portal hypertension in patients who have had chemotherapy, instead of using more invasive methods like liver biopsies.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment1000 (estimated)
SponsorNanfang Hospital, Southern Medical University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Guangzhou, Guangdong)
StatusRecruiting
StartedFebruary 28, 2024
Main results expectedDecember 31, 2028
Study endsDecember 31, 2029
Registry record updatedJuly 15, 2024
Trial IDNCT06500403 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18-80 who have received platinum-based chemotherapy for organ tumors.

Probably not a fit

Patients with liver cirrhosis, those who have undergone liver transplantation, or individuals with severe comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of measuring liver and spleen stiffness as non-invasive diagnostic tools for Porto-Sinusoidal Vascular Diseases (PSVD) in patients who have undergone platinum-based chemotherapy. The study will involve a single-center, prospective approach to gather data on the correlation between stiffness measurements and the diagnosis of PSVD, traditionally reliant on invasive liver biopsies. Additionally, the research seeks to identify potential biomarkers that could enhance the diagnostic process for PSVD.

Why it matters

Potential benefit: If successful, this study could provide a less invasive and more accurate method for diagnosing PSVD, improving patient care.

How similar studies have gone: Previous studies have indicated that liver and spleen stiffness measurements can accurately diagnose and predict outcomes for similar conditions, suggesting a promising approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Received platinum chemotherapy for organ tumors;
2. Ages 18-80;
3. sign the informed consent voluntarily.

Exclusion Criteria:

1. Liver pathology suggested cirrhosis;
2. Underwent liver transplantation;
3. Combined with hepatocellular carcinoma exceeding Milan criteria;
4. Complicated with severe heart, kidney, or lung failure;
5. Pregnant or lactating women;
6. Data is seriously missing;
7. Patients were judged not suitable for participation in this study by the researchers.

Where it's running

  • Nanfang hospital, Southern Medical Uiversity
    Guangzhou, Guangdong, China
    Recruiting

Study contacts

  • Principal investigator: Xiaofeng Zhang — Nanfang Hospital, Southern Medical University
  • Study coordinator: Xiaofeng Zhang
  • Email: 1282614092@qq.com
  • Phone: +8618565552050

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.